This effect on tumour growth was comparable to the effect of anti-PD-L1 blockade (Figure 6A,B), indicating in vivo activity of sPD-L1 as an antagonist of the PD-1 – PD-L1 axis. Here, SPDL1 is linked to neoplasm.